For these reasons, we consider InO to be the first line CD22 targeting therapy with CD22 CAR-T being reserved for patients in need of subsequent retrieval who maintain CD22 expression, or patients considered to be at very high risk for HSCT-related SOS (i.e., history of SOS or significant liver disease). This evidence concerns the gene CD22 and spondylo-ocular syndrome.